pharma is the sole category represented across all 1 tracked stories. Elizabeth Brannen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. U.S. Court of Appeals for the Federal Circuit appears in 1 tracked Biotech story from August 24, 2026.
Recent coverage · U.S. Court of Appeals for the Federal Circuit
1story
avg impact
0%positive
0%negative
100% neutral
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about U.S. Court of Appeals for the Federal Circuit
pharma is the sole category represented across all 1 tracked stories. Elizabeth Brannen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. U.S. Court of Appeals for the Federal Circuit appears in 1 tracked Biotech story from August 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering U.S. Court of Appeals for the Federal Circuit. Shared-story counts are live from our verified record — not editorial picks.
Stris & Maher's four-partner team adds Hatch-Waxman, PTAB, and biological sciences depth, giving biopharma companies expanded counsel for patent disputes across branded and generic markets.
U.S. Court of Appeals for the Federal Circuit is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.